Paracetamol-Tramadol and Paracetamol-caffeine Versus Placebo in the Emergency Discharge Treatment of Renal Colic
University of Monastir
1,500 participants
Apr 10, 2024
INTERVENTIONAL
Conditions
Summary
This is a prospective, randomized, single-blind study. Patients included in the study after successful treatment of the acute attack were randomized upon discharge from the Emergency Department into three groups: oral paracetamol-tramadol group, oral paracetamol-caffeine group and oral placebo group.
Eligibility
Inclusion Criteria4
- Age \> 18 years old.
- Consent to participate in the study.
- Pain in the flank/lumbar fossa of sudden onset with urine strips and/or imaging corresponding to the diagnosis of renal colic.
- Pain score at discharge \< 30 (visual analog scale - VAS or verbal numerical scale - VAS from 0 to 100).
Exclusion Criteria3
- Inability to appreciate pain according to the VAS.
- Pregnant or breastfeeding woman.
- Renal insufficiency with creatinine clearance \< 60 ml/min.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Each patient received 1 tablet \* 2/day synalvic (325 mg of paracetamol + 37.5 mg of tramadol) for 7 days
Each patient received 1 tab \* 3/d stopalgic extra (65mgcaffeine+500mg paracetamol) for 7 days
Each patient received 1 tab \* 3 / d of placebo (flour) every day for 7 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06345716